BioSpace News Archive

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity.

Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced the appointment of Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer.

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announced that the company’s Chief Medical Officer, Cedric O’Gorman, MD has resigned to pursue other opportunities.

Science 37 Holdings, Inc., the industry-leading Metasite™, announced the granting of an inducement equity award under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan.

XOMA Corporation, the Biotech Royalty Aggregator, announced the Company has granted Owen Hughes, the Company’s newly appointed Executive Chairman, two separate non-qualified stock options to purchase: 100,000 shares of the Company’s common stock at an exercise price of $18.66 per share and 75,000 shares of the Company’s common stock at an exercise price of $30.00 per share on January 3, 2023.

The mixed reality technology is an immersive digital experience designed to improve the blood donation process, attract new donors and motivate a younger generation to give blood.

Synthekine Inc. today announced the closing of a $100 million Series C financing led by The Column Group, with participation from both new and existing investors.

Bio-Rad Laboratories, Inc. will report its financial results for the fourth quarter and full year 2022 on Thursday, February 16, 2023, following the close of the market.

Keystone Bio announced today their participation as a keynote speaker at the Sachs 6th Annual Neuroscience Innovation Forum in San Francisco, CA.

Northwest Biotherapeutics reported positive results of voting at the Annual Shareholders Meeting on December 30, 2022 , and discussion at the Meeting (which was publicly available) about achievements in 2022 and anticipated activities in 2023.